Safety Concerns About Perisurgical Epoetin Treatment: Should We Add Antiplatelet Drugs to Perisurgical Epoetin Alfa Treatment?

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 21, Issue 4, 2007, Pages 623-624

  Basora, Misericordia ^a   Fita, Guillermina ^a   Matute, Purificación ^a   Díaz Ricart, Maribel ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTITHROMBOCYTIC AGENT; IRON; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT ERYTHROPOIETIN;

ADD ON THERAPY; ADULT; ANNULOPLASTY; CASE REPORT; DRUG SAFETY; ERYTHROCYTE; FEMALE; HEART SURGERY; HUMAN; INTERNATIONAL NORMALIZED RATIO; JEHOVAH'S WITNESS; LETTER; MITRAL VALVE REPLACEMENT; MITRAL VALVE STENOSIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK;

ANEMIA; EPOETIN ALFA; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HEMATINICS; HUMANS; MIDDLE AGED; MITRAL VALVE STENOSIS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; RISK FACTORS; TREATMENT OUTCOME;

EID: 34547230176     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2006.07.010     Document Type: Letter

References (10)

1. Moia M., Mannucci P.M., Vizzotto L., et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 330 (1987) 1227-1229
2. Cases A., Escolar G., Reverter J.C., et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 3 (1992) 668-672
3. Diaz-Ricart M., Etebanell E., Cases A., et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 82 (1999) 1312-1317
4. Malyszko J., Malyszko J.S., Borawski J., et al. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 77 (1995) 133-143
5. Finelli P.F., and Carley M.D. Cerebral venous thrombosis associated with epoetin alfa therapy. Arch Neurol 57 (2000) 260-262
6. Faris P.M., Ritter M.A., Abels R.I., and The American Erythropoietin Study Group. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. J Bone Joint Surg Am 78 (1996) 62-72
7. De Andrade J.R., Jove M., Landon G., et al. Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop 25 (1996) 533-542
8. Weber E.W., Slappendel R., Hemon Y., et al. Effects of epoetin alfa on blood transfusions and postoperative recovery in orthopaedic surgery: The European Epoetin Alfa Surgery Trial (EEST). Eur J Anaesthesiol 22 (2005) 249-257
9. De Andrade J.R., Frei D., and Guilfoyle M. Integrated analysis of thrombotic/vascular event occurrence in epoetin alfa-treated patients undergoing major, elective orthopedic surgery. Orthopedics 22 suppl (1999) S113-S118
10. Fuste B., Serradell M., Escolar G., et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 88 (2002) 678-685